Healthcare Industry News: Noven Pharmaceuticals
News Release - September 29, 2008
Noven Names Peter Amanatides as Vice President - Quality Assurance & Quality ControlMIAMI--(HSMN NewsFeed)--Noven Pharmaceuticals, Inc. (NASDAQ:NOVN ) today announced the appointment of Peter G. Amanatides as Vice President – Quality Assurance & Quality Control, effective immediately. In this role, Amanatides will lead all aspects of Noven’s quality functions.
Amanatides joins Noven with over 20 years of diverse pharmaceutical and biotechnology industry experience. Prior to Noven, he served DSM Pharmaceuticals, Inc. (a global contract manufacturer of oral and topical dosage forms, sterile products and active pharmaceutical ingredients) in several senior quality roles. Most recently, Amanatides served as Senior Director – Quality Operations & Regulatory Affairs, the senior-most quality officer at DSM Pharmaceuticals, with responsibility for all quality operations, including quality assurance, quality control, analytical development and regulatory affairs. Prior to his career at DSM, he was Director of Quality Systems at Celera Genomics, a human genome sequencing company then affiliated with Applera Corporation.
Amanatides holds a Master of Science degree in biotechnology and molecular biology from Hood College and a Bachelor of Science Degree in biology from Regents College. He has co-authored several scientific publications in the areas of genome sequencing and biotoxic compounds. While a member of the U.S. Army Medical Research Institute of Infectious Diseases, his work in the area of biotoxin detection earned an Army Achievement Medal.
“Peter will play an important role in our plan to establish Noven as a high growth specialty pharmaceutical company with uncompromised quality systems, controls and procedures,” said Peter Brandt, Noven’s President and Chief Executive Officer. “He has substantial experience and a record of accomplishment in the industry, and will lead our continuing efforts to enhance quality operations across the organization.”
Noven Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in the research, development, manufacture, marketing and sale of prescription pharmaceutical products. Noven’s business and operations are focused in three principal areas – transdermal drug delivery, the Novogyne joint venture, and Noven Therapeutics, Noven’s specialty pharmaceutical unit. For more information about Noven Pharmaceuticals, visit www.noven.com.
Source: Noven Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.